FY2025 EPS Estimates for CervoMed Lowered by Chardan Capital

CervoMed Inc. (NASDAQ:CRVO) – Investment analysts at Chardan Capital decreased their FY2025 earnings estimates for CervoMed in a research note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin now expects that the company will post earnings per share of ($2.68) for the year, down from their prior estimate of ($1.22). Chardan Capital has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share.

CervoMed (NASDAQ:CRVO) last released its earnings results on Monday, March 17th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%. The firm had revenue of $2.16 million for the quarter, compared to analyst estimates of $1.51 million.

CRVO has been the topic of several other reports. HC Wainwright lowered shares of CervoMed from a “buy” rating to a “neutral” rating in a report on Tuesday, December 17th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of CervoMed in a research report on Wednesday. Roth Mkm lifted their price objective on shares of CervoMed from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, March 18th. Roth Capital upgraded CervoMed to a “strong-buy” rating in a research note on Thursday, December 5th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of CervoMed in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.50.

CervoMed Price Performance

NASDAQ CRVO opened at $8.50 on Thursday. CervoMed has a one year low of $1.80 and a one year high of $25.92. The stock’s 50 day simple moving average is $3.85 and its 200 day simple moving average is $7.69. The firm has a market cap of $73.98 million, a PE ratio of -4.19 and a beta of 1.84.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CRVO. Geode Capital Management LLC boosted its holdings in shares of CervoMed by 13.9% in the third quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock worth $1,678,000 after acquiring an additional 14,042 shares during the period. State Street Corp boosted its holdings in shares of CervoMed by 28.1% in the 3rd quarter. State Street Corp now owns 104,456 shares of the company’s stock worth $1,525,000 after purchasing an additional 22,903 shares in the last quarter. Woodline Partners LP purchased a new position in shares of CervoMed during the fourth quarter worth approximately $175,000. Perigon Wealth Management LLC bought a new stake in CervoMed in the fourth quarter worth $147,000. Finally, Nuveen Asset Management LLC lifted its stake in shares of CervoMed by 113.6% in the 4th quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company’s stock valued at $97,000 after acquiring an additional 22,104 shares during the last quarter. Institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.